Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

ED Hottz, IG Azevedo-Quintanilha… - Blood, The Journal …, 2020 - ashpublications.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent pathogen
responsible for the coronavirus disease 2019 (COVID-19). Since its emergence, the novel …

Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19

Y Zaid, F Puhm, I Allaeys, A Naya, M Oudghiri… - Circulation …, 2020 - Am Heart Assoc
Rationale: In addition to the overwhelming lung inflammation that prevails in coronavirus
disease 2019 (COVID-19), hypercoagulation and thrombosis contribute to the lethality of …

Homocysteine as a biomarker in COVID-19

A Keskin - Features, Transmission, Detection, and Case Studies …, 2024 - Elsevier
Thrombosis and inflammation work in harmony in COVID-19 individuals. Therefore, COVID-
19 is potentially fatal and is characterized by a prolonged prothrombotic state. Despite the …

Neutrophil extracellular traps and thrombosis in COVID-19

Y Zuo, M Zuo, S Yalavarthi, K Gockman… - Journal of Thrombosis …, 2021 - Springer
Studies of patients with COVID-19 have demonstrated markedly dysregulated coagulation
and a high risk of morbid arterial and venous thrombotic events. Elevated levels of blood …

[HTML][HTML] Prevalence and clinical implication of thrombocytopenia and heparin-induced thrombocytopenia in patients who are critically ill with COVID-19

RK Lerner, D Lotan, D Oren, E Itelman, Y Neeman… - Clinical Medicine, 2022 - Elsevier
As the COVID-19 pandemic continues to evolve, different clinical manifestations are better
understood and studied. These include various haematologic disorders that have been …

COVID-19 induces cytokine storm and dysfunctional hemostasis

J Charles, VA Ploplis - Current Drug Targets, 2022 - ingentaconnect.com
Background: Infection with SARS-CoV-2 leads to COVID-19 which can manifest in various
ways from asymptomatic or mild disease to acute respiratory distress syndrome. The …

SARS-CoV-2 and plasma hypercoagulability

E Steadman, M Fandaros, W Yin - Cellular and Molecular Bioengineering, 2021 - Springer
Hypercoagulability has emerged as a prominent consequence of COVID-19. This presents
challenges not only in the clinic, but also in thrombosis research. Health and safety …

Longitudinal trend of plasma concentrations of extracellular vesicles in patients hospitalized for COVID-19

E Campello, CM Radu, C Simion, L Spiezia… - Frontiers in Cell and …, 2022 - frontiersin.org
Plasma concentrations of extracellular vesicles (EVs) originating from cells involved in
COVID-19-associated coagulopathy (CAC), their longitudinal trend and association with …

Not only lungs: COVID-19 hits platelets as well

D Bongiovanni, M Klug, M Valgimigli, I Bernlochner - 2022 - academic.oup.com
Despite the worldwide diffusion of SARS-CoV-2 infection, still little is known concerning the
mechanism leading to multi-organ damage in coronavirus disease 2019 (COVID-19). It is …

Antibody-induced procoagulant platelets in severe COVID-19 infection

K Althaus, I Marini, J Zlamal, L Pelzl… - Blood, The Journal …, 2021 - ashpublications.org
The pathophysiology of COVID-19–associated thrombosis seems to be multifactorial. We
hypothesized that COVID-19 is accompanied by procoagulant platelets with subsequent …